文献速递白血病淋巴瘤

FGFR1融合激酶调控MYC表达驱动干细胞白血病/淋巴瘤综合征发生

FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome.
PubMed 文献 · Leukemia · 2018-04-02

研究显示FGFR1激活伴随MYC上调,药物抑制FGFR1可下调MYC及其靶基因。荧光素酶报告实验表明FGFR1可直接调控MYC表达,且在嵌合FGFR1激酶存在时增强。SCLL细胞中颗粒酶B切割嵌合激酶产生核内截短FGFR1结合MYC调控区,但切割位点突变不影响MYC激活。胞质STAT5激活可不依赖截短FGFR1上调MYC,靶向MYC联合FGFR1抑制剂BGJ398协同抑制SCLL细胞增殖。

要点

  • FGFR1激活上调MYC,药物抑制FGFR1可下调MYC及其靶基因。
  • 颗粒酶B切割嵌合FGFR1产生核内截短体结合MYC调控区。
  • 胞质STAT5激活可不依赖截短FGFR1上调MYC。

核心结论

  • FGFR1融合激酶通过直接调控MYC表达及胞质STAT5激活等机制驱动SCLL发生,靶向MYC与FGFR1抑制联合可能用于SCLL治疗。

研究设计与样本

  • 本研究为体外细胞与分子机制研究。

主要发现

  • FGFR1激活伴随MYC上调,药物抑制FGFR1导致MYC及其靶基因下调。
  • 荧光素酶报告实验显示FGFR1可直接调控MYC表达,嵌合FGFR1激酶存在时该效应增强。
  • SCLL细胞中颗粒酶B切割嵌合激酶产生核内截短FGFR1,可结合MYC调控区;切割位点突变阻止核转位但不抑制MYC激活。
  • 胞质STAT5激活可不依赖截短FGFR1上调MYC。
  • shRNA敲低MYC及10054-F8靶向MYC功能抑制SCLL细胞增殖,并与FGFR1抑制剂BGJ398协同。

临床怎么用

  • 作者认为靶向MYC功能与FGFR1抑制联合可能用于SCLL治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oncogenic transformation of hematopoietic stem cells by chimeric fusion kinases causing constitutive activation of FGFR1 leads to a stem cell leukemia/lymphoma (SCLL) syndrome, accompanied by widespread dysregulation of gene activity. We now show that FGFR1 activation is associated with upregulation of MYC and pharmacological suppression of FGFR1 activation leads to downregulation of MYC and suppression of MYC target genes. Luciferase reporter assays demonstrate that FGFR1 can directly regulate MYC expression and this effect is enhanced in the presence of chimeric FGFR1 kinases. In SCLL cells, a truncated form of FGFR1 is generated by granzyme B cleavage of the chimeric kinases, producing a nucleus-restricted derivative that can bind MYC regulatory regions. Mutation of the granzyme B cleavage site prevents relocation to the nucleus but does not suppress MYC activation, suggesting additional mechanisms of MYC activation in the presence of cytoplasm-restricted chimeric kinases. We show that one of these mechanisms involves activating cytoplasmic STAT5, which upregulates MYC independent of the truncated FGFR1 kinase. Targeting MYC function using shRNA knockdown and 10054-F8 in SCLL cells leads to inhibition of cell proliferation and synergizes with the BGJ398 FGFR1 inhibitor, suggesting a combination therapy that could be used in the treatment of SCLL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hu T, Wu Q, Chong Y, et al. FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome. Leukemia. 2018. PMID: 29720732. doi:10.1038/s41375-018-0124-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。